Survival of patients with structurally-grouped  TP53  mutations in ovarian and breast cancers

Brandon-Luke L. Seagle; Kevin H. Eng; Monica Dandapani; Judy Y. Yeh; Kunle Odunsi; Shohreh Shahabi

doi:10.18632/oncotarget.4080

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers

Brandon-Luke L. Seagle _, Kevin H. Eng, Monica Dandapani, Judy Y. Yeh, Kunle Odunsi and Shohreh Shahabi

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:18641-18652. https://doi.org/10.18632/oncotarget.4080

Metrics: PDF 1988 views | HTML 2263 views | ?

Abstract

Brandon-Luke L. Seagle1, Kevin H. Eng2, Monica Dandapani1, Judy Y. Yeh1, Kunle Odunsi3, Shohreh Shahabi4

1Department of Obstetrics, Gynecology and Reproductive Sciences, Western Connecticut Health Network, Danbury, CT, USA

2Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA

3Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

4Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Prentice Women’s Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Correspondence to:

Shohreh Shahabi, e-mail: [email protected]

Keywords: ovarian neoplasms, breast neoplasms, TP53 gene, mutation, biological markers

Received: March 07, 2015 Accepted: June 12, 2015 Published: June 22, 2015

ABSTRACT

The objective of this study was to determine if ovarian cancer patients with a TP53 mutation grouped by location of the mutation within the p53 protein structure exhibit differential survival outcomes. Data from patients with high grade serous ovarian cancer (HGS OvCa) (N = 316) or breast cancer (BrCa) (N = 981) sequenced by The Cancer Genome Atlas (TCGA) was studied by Kaplan-Meier and Cox proportional hazards survival analysis. A TP53 DNA binding domain (BD) missense mutation (MM) occurred in 58.5% (185/316) of HGS OvCas and 16.8% (165/981) of BrCas. Patients with a TP53 DNA BD MM grouped by structural location had significantly different overall survival (OS) and progression free survival (PFS). Median OS (months) of HGS OvCa patients by structural group were: Sheet-loop-helix stabilizers, 31.1; DNA minor groove residue R248, 33.6; Wild-type, 34.2; all other MMs, 44.5; DNA major groove residues, 84.1, and zinc ion coordinating residues, 87.0 (log-rank p = 0.006). PFS of DNA major groove MM cases was longer than TP53 wild-type cases (19.1 versus 10.1 months, log-rank p = 0.038). HGS OvCa and BrCa patients with structurally-grouped TP53 DNA BD MMs have different survival outcomes.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4080

Publication Alerts

Research Papers:

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers

Abstract